Vaage AM, Nakken O (2025)
Author Response: Physical Activity, Fitness, and Long-Term Risk of Amyotrophic Lateral Sclerosis: A Prospective Cohort Study
Neurology, 104 (9), e209962
DOI 10.1212/WNL.0000000000209962, PubMed 40249895

Schytte T, Knap MM, Kristiansen C, Appelt AL, Khalil A, Peucelle C, Lutz CM, Møller DS, Sande EPS, Sundby F, Persson G, Schmidt H, Land LH, Rogg L, Pøhl M, Lund MD, Nielsen M, Levin N, Hansen O, Thing RS, Borissova S, Halvorsen T, Nielsen TB, Hansen TS, Haakensen VD et al. (2025)
Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non-Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial
J Clin Oncol, JCO2401386 (in press)
DOI 10.1200/JCO-24-01386, PubMed 40249893

Niemann CU, Dubois J, Nasserinejad K, da Cunha-Bang C, Kersting S, Enggaard L, Veldhuis GJ, Mous R, Mellink CHM, van der Kevie-Kersemaekers AF, Dobber JA, Bjørn Poulsen C, Razawy W, Hollestein R, Frederiksen H, Janssens A, Schjødt I, Dompeling EC, Ranti J, Brieghel C, Mattsson M, Bellido M, Tran HTT, Kater AP, Levin MD (2025)
Long term follow-up of MRD guided treatment of Ibrutinib plus Venetoclax for Relapsed CLL: phase 2 VISION/HO141 trial
Blood Adv (in press)
DOI 10.1182/bloodadvances.2024015180, PubMed 40249856